Physicians

Department / Division
Medicine / Medicine-Nephrology

Address
DUMC 2747
Durham, NC 27710

Appointment Telephone
919-668-7630

Office Telephone
919-660-6865

Fax Telephone
919-684-4476

Training

• MD, Duke University School of Medicine, 1987

Residency

• Internal Medicine, Duke University Medical Center, 1987-1990
• Nephrology, Duke University Medical Center, 1990-1992

Clinical Interests
Transplantation, consultative nephrology

Research Interests
As a Clinician and Clinical Researcher in the Division of Nephrology my practice is mainly focussed on patients with end stage renal disease. I am co-Director of a maintenance hemodialysis unit which cares for approximately 110 patients on maintenance hemodialysis. In addition, I see patients three days weekly through the Private Diagnostic Clinic. We see a variety of consultative nephrology problems, but our major focus remains Aend stage renal disease and renal transplantation@. In the Renal Transplant Clinic, we see patients both pre- and post-transplant. Over the last two years we have transplanted 90-100 patients annually and care for several hundred other patients who are on the active transplant list.

My research interests thus relate primarily to end stage renal disease. In the dialysis unit we are currently involved in a multi-center NIH-sponsored trial called the AHEMO Trial@, which is looking at causes of long-term morbidity and mortality in the dialysis population and the effect on the dialysis prescription. In addition, our group has been active in maintenance of long-term hemodialysis access in the prospective of monitoring of vascular access to extend long-term graft survival. In the transplantation arena, we will soon be stating another multi-center trial to evaluate a new anti-lymphocyte antibody for the treatment of acute cellular rejection. This will be a multi-center randomized trial evaluating this new antibody versus OKT-3, which is currently standard of care. We are also interested in bone disease after transplantation and the prevention of acute rejection with other pharmacologic mechanisms and are establishing trials and interventions to evaluate these.

KEY WORDS:
End stage renal disease, vascular access, renal transplantation, post-transplantation osseous disorders, consultative Nephrology.

Industry Relationships and Collaborations (What's this?)

This faculty member has no reported relationships with industry.